Open AccessGene Expression Profiles Predict Emergence of Psychiatric Adverse Events in HIV/HCV-Coinfected Patients on Interferon-Based HCV Therapy
Author(s) -
Joseph J. Rasimas,
Antonios Katsounas,
Haniya Raza,
Alison Murphy,
Jun Yang,
Richard A. Lempicki,
Anu Osinusi,
Henry Masur,
Michael A. Polis,
Shyam Kottilil,
Donald L. Rosenstein
Publication year - 2012
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31824c17c4
Subject(s) - ribavirin , medicine , hepatitis c , immunology , alpha interferon , interferon , pegylated interferon , hepatitis c virus , gene expression profiling , gene , gene expression , biology , virus , genetics
The efficacy of pegylated interferon-α and ribavirin (pegIFN/RBV) in the treatment of Hepatitis C infection is limited by psychiatric adverse effects (IFN-PE). Our study examined the ability of differential gene expression patterns before therapy to predict emergent IFN-PE among 28 HIV/HCV-coinfected patients treated with pegIFN-α2b/RBV.